BG Medicine Profile

USD 0.002  4.17%

Exercise of in-the-money or at-the-money derivative position by Stelios Papadopoulos of 5773 shares of BG Medicine

BG Medicine insider trading alert for exercise of common stock by Stelios Papadopoulos, the corporate stakeholder, on May 21, 2018. This event was filed by Bg Medicine Inc with SEC on 2011-12-01. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

BG Medicine Summary

BG Medicine (BGMD) is traded on OTC Market in USA. It is located in 303 Wyman Street and employs 5 people. The company currently falls under 'Nano-Cap' category with current market capitalization of 659.72 K. BG Medicine conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 11.37 M outstanding shares of which 630.05 K shares are currently shorted by private and institutional investors with about 2.66 trading days to cover. BG Medicine currently holds about 1.52 M in cash with (3.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check BG Medicine Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 0.046HorizonTargetOdds Above 0.046
28.47%30 days 0.046 71.46%
Based on normal probability distribution, the odds of BG Medicine to move above current price in 30 days from now is about 71.46% (This BG Medicine probability density function shows the probability of BG Medicine Stock to fall within a particular range of prices over 30 days) .

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Ifp Advisors IncCommon Shares75.00.0
Agtc Partners LpCommon Shares863.3 K354 K
View BG Medicine Diagnostics

Selected BG Medicine Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

BG Medicine Against Markets

Current Ratings

BG Medicine 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for BG Medicine are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG Medicine operates under Diagnostics Research classification in USA and traded on OTC Market. It employs 5 people. more
NameBG Medicine
President CEO, DirectorPaul SohmerView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address303 Wyman Street
ExchangeOTC Market
CIK Number0001407038
IndustryPharmaceutical Products
Phone781 890 1199
CurrencyUSD - US Dollar

BG Medicine Corporate Directors

James Connor Director
Harry Wilcox Director
Stelios Papadopoulos Independent Director, MBA
Check also Trending Equities. Please also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.